FLNT — Recent News Coverage
All news mentioning FLNT in ESEN's AI-graded feed
News stories with FLNT as an affected ticker. Each article is graded by ESEN AI for impact level and direction (up/down/flat) on FLNT. See /coverage/FLNT for the 30-day aggregate.
SEEKINGALPHA.COM
·
2026-08-12
LOW
BULLISH
CORR0.55
Fluent: Low Valuation In A Growing Sector (NASDAQ:FLNT)
$FLNT
◈ ESEN AI
FLNT received a Buy rating anchored on 2Q26 financial results and valuation positioning relative to secular tailwinds in commerce media advertising. The analyst argument centers on a perceived disconnect between the com…
SEEKINGALPHA.COM
·
2026-08-11
LOW
NEUTRAL
CORR0.35
Fluent, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:FLNT) 2026-08-11
$FLNT
◈ ESEN AI
FLNT published its Q2 2026 earnings call presentation on August 11, 2026, a scheduled disclosure typical of quarterly earnings cycles. The release itself constitutes a procedural announcement rather than a catalyst-driv…
MANILATIMES.NET
·
2026-07-21
LOW
NEUTRAL
CORR0.15
Fluent, Inc. to Attend 46th Annual Canaccord Genuity Growth Conference
$FLNT
◈ ESEN AI
Fluent, Inc. (FLNT) has announced executive participation at the 46th Annual Canaccord Genuity Growth Conference, with CEO Don Patrick and CFO Ryan Perfit scheduled to present and meet with investors. This is a routine …
MANILATIMES.NET
·
2026-07-17
NEUTRAL
NEUTRAL
CORR0.35
FLUENT Provides Update and Supplemental Disclosure on Circular to Approve All-Stock Transaction With Vireo Growth Inc.
$FLNT
◈ ESEN AI
FLUENT Corp. has distributed its management information circular to shareholders ahead of a July 28, 2026 special meeting to vote on an all-stock merger with Vireo Growth Inc. This represents a significant corporate res…
MANILATIMES.NET
·
2026-07-09
NEUTRAL
BULLISH
CORR0.42
CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia
$FLNT
◈ ESEN AI
CervoMed has completed enrollment in a Phase 2 clinical trial evaluating neflamapimod for nonfluent variant primary progressive aphasia (nfvPPA), a rare neurodegenerative condition classified as frontotemporal dementia.…
EXPLORE OTHER FILTERS